Taysha Gene Therapies (TSHA) Income from Continuing Operations (2022 - 2025)
Historic Income from Continuing Operations for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to -$30.9 million.
- Taysha Gene Therapies' Income from Continuing Operations fell 2962.42% to -$30.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$94.1 million, marking a year-over-year decrease of 1565.51%. This contributed to the annual value of -$84.6 million for FY2024, which is 1456.17% down from last year.
- Per Taysha Gene Therapies' latest filing, its Income from Continuing Operations stood at -$30.9 million for Q3 2025, which was down 2962.42% from -$24.9 million recorded in Q2 2025.
- In the past 5 years, Taysha Gene Therapies' Income from Continuing Operations ranged from a high of -$15.0 million in Q4 2023 and a low of -$55.1 million during Q4 2022
- Over the past 4 years, Taysha Gene Therapies' median Income from Continuing Operations value was -$23.8 million (recorded in 2024), while the average stood at -$26.7 million.
- Its Income from Continuing Operations has fluctuated over the past 5 years, first surged by 7269.39% in 2023, then tumbled by 4336.02% in 2024.
- Quarter analysis of 4 years shows Taysha Gene Therapies' Income from Continuing Operations stood at -$55.1 million in 2022, then soared by 72.69% to -$15.0 million in 2023, then dropped by 21.39% to -$18.3 million in 2024, then tumbled by 69.11% to -$30.9 million in 2025.
- Its Income from Continuing Operations was -$30.9 million in Q3 2025, compared to -$24.9 million in Q2 2025 and -$20.1 million in Q1 2025.